Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: THIEL PETER

Tue, 17 Feb 2026 16:49:00 +0000

si-local-file:///var/storage/secattach/20260217/26014528.html

Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: THIEL PETER

Tue, 17 Feb 2026 16:49:00 +0000

si-local-file:///var/storage/secattach/20260217/26014528.html

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Tue, 17 Feb 2026 08:00:00 +0000

TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36^th Annual Healthcare Life Sciences Conference on February 26, 2026. The corporate presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days.

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Tue, 17 Feb 2026 08:00:00 +0000

Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: Otto Erik

Tue, 10 Feb 2026 16:43:00 +0000

si-local-file:///var/storage/secattach/20260210/25976531.html

Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: Otto Erik

Tue, 10 Feb 2026 16:43:00 +0000

si-local-file:///var/storage/secattach/20260210/25976531.html

Chemomab publishes phase 2 PSC trial results in medical journal

Tue, 02 Dec 2025 08:01:32 +0000

Chemomab Therapeutics Ltd. (NASDAQ: CMMB) announced that results from its Phase 2 SPRING trial of nebokitug in patients with primary sclerosing cholangitis were published in the American Journal of Gastroenterology.

The study evaluated nebokitug, a monoclonal antibody targeting CCL24, in 76 patients across 33 sites in the United States, United Kingdom, Germany, Spain and Israel. Patients received either intravenous nebokitug at 10 mg/kg, 20 mg/kg, or placebo every three weeks for 15 weeks.

According to the publication, nebokitug was generally safe and well tolerated for up to 48 weeks of treatment. The study showed numerical improvements in biomarkers for inflammation and fibrosis,

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Tue, 02 Dec 2025 08:00:00 +0000

—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial—

TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current issue of the American Journal of Gastroenterology.¹

The

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Tue, 02 Dec 2025 08:00:00 +0000

The

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Mon, 24 Nov 2025 08:00:00 +0000

TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space.

Dr. Mor will present a corporate overview and will be available for

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Mon, 24 Nov 2025 08:00:00 +0000

Dr. Mor will present a corporate overview and will be available for

StreetInsider.com News Articles

Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: THIEL PETER

Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: THIEL PETER

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: Otto Erik

Form SCHEDULE 13G/A Chemomab Therapeutics Filed by: Otto Erik

Chemomab publishes phase 2 PSC trial results in medical journal

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit